# Practical Feasibility Assessment: Surviving Hypotheses
## Identifying Surviving Hypotheses
Based on the critique's revised confidence scores, the following hypotheses warrant feasibility assessment:
| Hypothesis | Revised Confidence | Status |
|------------|-------------------|--------|
| **H3: ATP Depletion from Mitochondrial Tau Pathology** | 0.55 | **Primary candidate** |
| **H2: Calcium-Mediated Scramblase Activation via TMEM16F** | 0.40 | Secondary candidate |
| **H6: TMEM16F Upregulation via NFAT Signaling** | 0.40 | Secondary candidate |
| H4: Caspase-Mediated Flippase Cleavage | 0.35 | Marginal—not assessed |
| H1: Kinase Convergence | 0.25 | Eliminated |
| H5: Direct Membrane Displacement | Not scored | Eliminated in critique |
| H7: Exosome-Mediated Spread | 0.30 | Eliminated |
**Assumption:** H3, H2, and H6 remain testable and mechanistically coherent enough to justify therapeutic development consideration.
---
## H3: Mitochondrial Tau Pathology and ATP Depletion
### 1. Druggability Assessment
**Target Quality:** High
| Parameter | Assessment |
|-----------|------------|
| **Target identity** | DRP1 (DNM1L)—well-validated protein with crystal structure solved |
| **Location** | Cytosolic (dynamin-like GTPase) |
| **Function** | Mediates mitochondrial fission; directly interacts with tau |
| **Known interactors** | Fis1, Mff, MiD49/51 (published literature) |
| **Genetic evidence** | Knockout mice viable (partial redundancy with Drp1 paralogs) |
**Downstream therapeutic nodes:**
| Node | Tractability | Comments |
|------|--------------|----------|
| DRP1 GTPase activity | High | Catalytic pocket druggable; Mdivi-1 proof-of-concept |
| Mitochondrial dynamics | Moderate | Multiple proteins, network effects |
| Cellular ATP levels | Low as direct target | Emergent property; not a protein target |
**Druggability score: 7/10**
The pathway has clear, validated targets with existing tool compounds.
---
### 2. Existing Compounds and Clinical Trials
**Tier 1: Repurposable compounds (known safety profiles)**
| Compound | Mechanism | Clinical Status | Indication |
|----------|-----------|-----------------|------------|
| **Mdivi-1** | DRP1 GTPase inhibitor | Preclinical only | Stroke, cardiac ischemia, ALS |
| **Pyruvate** | Metabolic substrate | Dietary supplement | General metabolic support |
| **Coenzyme Q10** | Electron transport chain | Phase III completed | Parkinson's, Huntington's |
| **MitoQ** | Mitochondria-targeted antioxidant | Phase II completed | Parkinson's, Alzheimer's |
| **Nicotinamide riboside (NR)** | NAD+ precursor | Dietary supplement | Aging, metabolic disorders |
| **Edaravone** | Antioxidant | FDA-approved | ALS |
**Tier 2: Clinical candidates targeting related mechanisms**
| Compound | Mechanism | Clinical Phase |
|----------|-----------|----------------|
| **BMC-134** (Drp1 inhibitor series) | DRP1 oligomerization | Preclinical |
| **Pyrvinium** | Drp1 phosphorylation inhibition | Cancer trials (withdrawn) |
| **Idebenone** | Synthetic CoQ10 analog | Phase III | Friedreich's ataxia |
| **Omavelorone** | Nrf2 activator | Phase II | Friedreich's ataxia |
**Critical gap:** No DRP1-selective inhibitor has entered human trials for neurodegeneration. Mdivi-1 has suboptimal pharmacokinetics and off-target effects.
**Clinical trial landscape (tauopathy focus):**
- No current trials explicitly targeting mitochondrial fission in Alzheimer's
- Several trials target general mitochondrial function (CoQ10, NR, MitoQ)
- Trials in Parkinson's (which also involves mitochondrial dysfunction) have been largely negative for CoQ10
---
### 3. Development Cost and Timeline
**Scenario A: Repurposing existing compounds (fastest path)**
| Phase | Duration | Cost Estimate |
|-------|----------|---------------|
| Indicational validation | 1-2 years | $2-5M |
| Phase II trial | 2-3 years | $15-30M |
| Regulatory pathway | 6-12 months | $1-3M |
| **Total (if successful)** | **4-6 years** | **$20-40M** |
**Scenario B: Novel DRP1 inhibitor development**
| Phase | Duration | Cost Estimate |
|-------|----------|---------------|
| Lead identification | 1-2 years | $3-5M |
| Lead optimization | 2-3 years | $10-20M |
| IND-enabling studies | 1-2 years | $5-10M |
| Phase I safety | 1-2 years | $10-15M |
| Phase II proof-of-concept | 2-3 years | $30-50M |
| **Total** | **8-12 years** | **$60-100M** |
**Likelihood of regulatory success:**
Given that mitochondrial dysfunction is not an approved indication for neurodegeneration, efficacy would need to be demonstrated de novo. Historical success rate for Alzheimer's disease-modifying therapies: ~2-3%.
---
### 4. Safety Concerns
**Critical safety issues:**
| Risk | Severity | Mitigation |
|------|----------|------------|
| **Developmental toxicity** | High | DRP1 is essential for embryonic mitophagy; avoid in pregnant women |
| **Off-target GTPases** | Moderate | Dynamin family selectivity required |
| **Inhibition of protective mitophagy** | Moderate | May impair clearance of damaged mitochondria |
| **Tissue-specific effects** | Moderate | Mitochondrial dynamics vary by cell type |
| **Drug-drug interactions** | Low-Moderate | MitoQ has known CYP interactions |
**The Mdivi-1 problem:**
Mdivi-1 inhibits DRP1 at micromolar concentrations but also inhibits dynamin-1 and dynamin-2 at similar concentrations. This creates:
- Potential vascular effects (dynamin-dependent endocytosis)
- Unclear mechanism attribution in vivo
**Off-label opportunity:**
MitoQ and CoQ10 have safety profiles suitable for long-term use in neurodegeneration populations (elderly, polypharmacy). These could be rapidly deployed in compassionate use or investigator-initiated trials.
---
## H2: Calcium-Mediated TMEM16F Activation
### 1. Druggability Assessment
**Target Quality:** Moderate
| Parameter | Assessment |
|-----------|------------|
| **Primary target** | TMEM16F (ANO6)—calcium-activated scramblase |
| **Structural information** | Cryo-EM structures available (2020-2022) |
| **Challenge** | TMEM16F is a 9-transmembrane protein with complex calcium regulation |
| **Alternative targets** | SERCA pump, IP3 receptors, RyR channels |
**Why this is harder than H3:**
| Issue | Impact |
|-------|--------|
| TMEM16F lacks known drug-binding pockets | Direct inhibition is novel chemistry territory |
| Calcium is a ubiquitous second messenger | Global calcium modulation is highly toxic |
| TMEM16F is membrane-embedded | Cell permeability challenge for inhibitors |
**Druggability score: 4/10**
Therapeutic modulation is feasible but requires careful target deconvolution.
---
### 2. Existing Compounds and Clinical Trials
**Tier 1: Calcium modulators (available, but pleiotropic)**
| Compound | Mechanism | Limitation |
|----------|-----------|------------|
| **BAPTA-AM** | Intracellular calcium chelator | Only cell culture use; ester hydrolysis |
| **Ryanodine** | Ryanodine receptor blocker | Cardiac effects; narrow therapeutic window |
| **Dantrolene** | Ryanodine receptor stabilizer | Used for malignant hyperthermia; limited brain penetration |
| **Verapamil** | L-type calcium channel blocker | Cardiovascular effects; may not affect neuronal calcium |
| **Nimodipine** | L-type calcium channel blocker | Used for subarachnoid hemorrhage; CNS penetration |
**Tier 2: ER stress modulators**
| Compound | Mechanism | Status |
|----------|-----------|------------|
| **TUDCA** (tauroursodeoxycholic acid) | ER stress inhibitor | Phase III completed (cholestasis); Phase II (Parkinson's) |
| **Salubrinal** | eIF2α phosphatase inhibitor | Preclinical; protects against ER stress |
| **CCPA** | Store-operated calcium entry blocker | Preclinical only |
**Critical gap:**
No specific TMEM16F inhibitors exist. ANO6 knockout mice exist but have not yielded pharmacological tool compounds.
---
### 3. Development Cost and Timeline
**Scenario A: Calcium modulation with existing drugs (repurposing)**
| Phase | Duration | Cost Estimate |
|-------|----------|---------------|
| Target validation (which calcium source?) | 2-3 years | $5-10M |
| Repurposing study (nimodipine, TUDCA) | 3-4 years | $20-40M |
| **Total** | **5-7 years** | **$25-50M** |
**Scenario B: Novel TMEM16F antagonist**
| Phase | Duration | Cost Estimate |
|-------|----------|---------------|
| Target validation | 2 years | $5M |
| HTS/lead finding | 2-3 years | $10-15M |
| Lead optimization | 2-3 years | $15-25M |
| IND + Phase I | 2-3 years | $20-30M |
| **Total** | **8-11 years** | **$50-75M** |
**Additional complication:**
Unlike H3 (clear target: DRP1), H2 requires first establishing *which* calcium source is primary—ER release, mitochondrial leakage, or extracellular entry. Without this, compound development is unfocused.
---
### 4. Safety Concerns
**Critical safety issues:**
| Risk | Severity | Comments |
|------|----------|----------|
| **Cardiovascular collapse** | High | Calcium channel blockers can cause hypotension |
| **Immunosuppression** | Moderate | TUDCA affects bile acid signaling broadly |
| **Impaired protective calcium signaling** | High | Calcium dysregulation is bidirectional |
| **Narrow therapeutic index** | High | Calcium homeostasis is tightly regulated |
| **Tachyphylaxis** | Moderate | Calcium channel blockers show diminishing returns |
**The fundamental problem:**
Calcium is not a disease-specific signal. Drugs that reduce calcium will have effects in every calcium-dependent process, from muscle contraction to neurotransmitter release to cardiac rhythm. Achieving selective effects on TMEM16F-mediated PS exposure while preserving normal calcium signaling is extremely challenging.
---
## H6: NFAT-Calcineurin-TMEM16F Transcriptional Pathway
### 1. Druggability Assessment
**Target Quality:** Low-Moderate
| Parameter | Assessment |
|-----------|------------|
| **Primary target** | NFAT transcription factors (NFATC2, NFATC3) |
| **Intermediate target** | Calcineurin (PPP3CA) |
| **Downstream target** | ANO6 expression |
| **Challenge** | Transcriptional programs are network-level; single-target inhibition insufficient |
**Why this is the hardest target:**
| Issue | Impact |
|-------|--------|
| Transcription factor druggability | NFAT has no deep pockets; classic "undruggable" target class |
| Gene expression noise | Chronic disease requires sustained pathway modulation |
| Cell-type specificity | NFAT functions in many cell types |
**Druggability score: 3/10**
Transcriptional targets are notoriously difficult for small-molecule intervention.
---
### 2. Existing Compounds and Clinical Trials
**Tier 1: Calcineurin inhibitors (immunosuppressants)**
| Compound | Mechanism | Status | Limitation |
|----------|-----------|--------|------------|
| **Cyclosporine A** | Calcineurin inhibitor | FDA-approved | Immunosuppression, nephrotoxicity |
| **FK506 (tacrolimus)** | Calcineurin inhibitor | FDA-approved | Immunosuppression, neurotoxicity |
| **Rapamycin (sirolimus)** | mTOR inhibitor | FDA-approved | Metabolic effects |
**Tier 2: NFAT pathway modulators**
| Compound | Mechanism | Status |
|----------|-----------|------------|
| **VIVIT peptide** | NFAT inhibitor | Research tool only |
| **AR-42 (HDAC inhibitor)** | NFAT acetylation | Phase I/II (cancer) |
| **Voclosporin** | Calcineurin inhibitor | FDA-approved (lupus nephritis) |
**Critical gap:**
No CNS-penetrant, non-immunosuppressive calcineurin or NFAT inhibitor exists. Immunosuppressive drugs are contraindicated in elderly neurodegeneration patients.
---
### 3. Development Cost and Timeline
**Scenario A: Repurposing calcineurin inhibitors**
| Phase | Duration | Cost |
|-------|----------|------|
| Repurposing study | 2-3 years | $15-25M |
| Safety/toxicity assessment in elderly | 2-3 years | $20-30M |
| **Total** | **4-6 years** | **$35-55M** |
**But:** Immunosuppression risk likely precludes this indication.
**Scenario B: Novel non-immunosuppressive calcineurin inhibitor**
| Phase | Duration | Cost |
|-------|----------|------|
| Target validation | 2-3 years | $5-10M |
| Lead finding (novel chemotypes) | 3-4 years | $15-25M |
| Lead optimization (remove immunosuppression) | 2-3 years | $15-20M |
| IND + Phase I | 2 years | $20-30M |
| **Total** | **